CMS Administrator Seema Verma on Wednesday (Oct. 30) said CMS is pursuing policies to allow outcomes-based drug contracts to circumvent Medicaid best price requirements, but said she is concerned the arrangements could lead to higher launch prices for drugs. If drug makers understand that they would be giving discounts on drugs if the medicines do not produce certain patient outcomes, that calculation may be built into drugs’ base prices, Verma said. “I think we should be cautious on this. One...